Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cubist Pharmaceuticals, a biopharmaceutical company, has filed a patent infringement lawsuit against Teva Parenteral Medicines, Teva Pharmaceuticals USA, and Teva Pharmaceutical Industries.
Subscribe to our email newsletter
The complaint, which was filed in the US District Court of Delaware, alleges infringement of US patents, which expire on September 24, 2019, and another US patent which expires on June 15, 2016.
Cubist has filed the lawsuit in response to an abbreviated new drug application filed by Teva Parenteral Medicines seeking the FDA approval to market a generic version of daptomycin prior to the expiration of Cubist’s patent rights. Daptomycin is marketed in the US and internationally under the brand name Cubicin as therapy for serious skin and bloodstream infections caused by certain gram-positive bacteria.
Michael Bonney, president and CEO of Cubist, said: “We have confidence in our patents and will continue to take all appropriate actions needed to protect our intellectual property rights related to Cubicin.”